Optimizing maternal and neonatal outcomes with postpartum contraception: impact on breastfeeding and birth spacing

Table 1 Medical Eligibility Criteria [CDC/WHO]

Method	<10 min	<48 h	<21 days	21 to <30 days	30-42 days	42 days-6 months	>6 months
Breastfeeding Women	Category [CDC/WHO]
Combined hormonal contraceptives	4/4	4/4	4/4	3/4	2^a/4	2/3^c	2/2
Progestin-only pills	2/2	2/2	2/2	2/2	1/2	1/1	1/1
DMPA	2/3	2/3	2/3	2/3	1/3	1/1	1/1
Etonogestrel implant	2/2	2/2	2/2	2/2	1/2	1/1	1/1
Levonorgestrel intrauterine device	2/2	2/2	2/3	2^b/3^b	1^b/1^b	1/1	1/1
Copper intrauterine device	1/1	2/1	2/3	2^b/3^b	1^b/1^b	1/1	1/1
Nonbreastfeeding Women	Category [CDC/WHO]
Combined hormonal contraceptives	4/3^d	4/3^d	4/3^d	2^a/2^a	2^a/2^a	1/1	1/1
Progestin-only pills	1/1	1/1	1/1	1/1	1/1	1/1	1/1
DMPA	1/1	1/1	1/1	1/1	1/1	1/1	1/1
Etonogestrel implant	1/1	1/1	1/1	1/1	1/1	1/1	1/1
Levonorgestrel intrauterine device	1/1	2/1	2/3	2^b/3^b	1^b/1^b	1/1	1/1
Copper intrauterine device	1/1	2/1	2/3	2^b/3^b	1^b/1^b	1/1	1/1

^a CDC & WHO Category 3 for women with other risk factors for VTE: 35 years old or older, previous VTE, thrombophilia, immobility, peripartum transfusion, peripartum cardiomyopathy, obesity, peripartum hemorrhage, cesarean delivery, preeclampsia, or smoking
^b Refers to 28 days for intrauterine device insertion timing
^c Refers to women who are primarily breastfeeding
^d WHO Category 4 for women with other risk factors for VTE

ISSN: 2054-958X